Why is "CD47" trending?

Search Interest Perspective

• CD47 Antibody Combo Shows Meaningful Activity in Previously Untreated AML - CancerNetwork
• 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis - American Heart Association Journals
• Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer - Nature
• Targeting the CD47-SIRPα axis continues to show promise in solid tumours - ESMO Daily Reporter
• CD47 Protein May Predict Evorpacept Success in Metastatic Breast Cancer - Cure Today
• CD47 inhibits phagocytosis through Vav dephosphorylation - Rockefeller University Press
• CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer - Targeted Oncology
• CD47 Expression Linked to Durable Responses With Zanidatamab/Evorpacept in Pretreated HER2+ Metastatic Breast Cancer - OncLive
• Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity - Wiley & Sons
• Pfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager - Fierce Biotech
• Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer | British Journal of Cancer - Nature
• Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance - ESMO Daily Reporter
• High CD47 Expression Level Predicts Response to Evorpacept/Zanidatamab in HER2+ Breast Cancer - OncLive
• Core Fucosylation Represses SMURF1-Dependent Degradation of CD47 to Promote Tumor Immune Evasion - Wiley & Sons
• Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma - Nature
• CD47 as a prognostic biomarker and potential immunotherapy target in penile squamous cell carcinoma - Nature
• CD47 induces T cell exhaustion through interaction with thrombospondin-1 - Nature
• IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer - Nature
• Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl cyclase modulates therapeutic antibody binding - Nature
• Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma - Nature
• Akeso spotlights AML data for anti-CD47 mAb ahead of EHA - FirstWord Pharma
• CD47 emerges as a central immune regulator in liver and gastrointestinal diseases - EurekAlert!
• The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity - Wiley Online Library
• A new glioblastoma target: Blocking CD47 protein's tumor-driving role may slow growth - Medical Xpress
• Akeso’s Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML) - 康方生物
• New T Cell–Suppressive Pathway Highlights TSP-1–CD47 as Immunotherapy Booster - Genetic Engineering and Biotechnology News
• HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology - PR Newswire
• ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs - Yahoo Finance
• New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - GlobeNewswire
• ImmuneOncia bets on structural redesign to overcome CD47 setbacks - koreabiomed.com
• Targeting the matrix for anti-tumor T cell revival - EurekAlert!
• Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy - American Heart Association Journals
• Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer - ScienceDirect.com
• Beyond CD47: CD43 Emerges as Critical Immune Checkpoint in AML - Pharmacy Times
• Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and more - Endpoints News
• Glioblastoma Growth Mechanism Identified, Pointing to Potential Therapeutic Targets - Genetic Engineering and Biotechnology News
• Genome-wide CRISPR screen for human factors involved in alternative polyadenylation based on differential localization of CD47 - Nature
• Repurposing Cardiac Glycosides to Potentiate CD47 Blockade through Calreticulin-mediated Phagocytic Effects for Lung Cancer Treatment - Wiley & Sons
• ALX Oncology reports breast cancer trial data with CD47 biomarker - Investing.com
• CD24 emerges as the next macrophage checkpoint - Drug Target Review
• Dual Targeting Approach Improves Immunotherapy Response in Glioblastoma | Newswise - Newswise
• Inhibition of Macrophage ARID3A Alleviates Myocardial Ischemia-Reperfusion Injury After Heart Transplantation by Reducing THBS1/CD47 Signaling-Mediated Neutrophil Extracellular Traps Formation - Wiley & Sons
• In ALX breast cancer study, 5 of 5 high-CD47 patients responded - Stock Titan
• Immunogenic cell death unlocks the potential for combined radiation and immunotherapy - PNAS
• ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - Yahoo Finance
• ALX Oncology Q1 2026 slides: 100% response validates CD47 strategy - Investing.com
• TWINPEAK study: Spevatamig Plus Gemcitabine and Nab-Paclitaxel as 1L Therapy in CLDN18.2 Positive mPDAC - Oncodaily
• Anti‐CD47 drug interference in pre‐transfusion testing can be overcome by antigen masking - Wiley Online Library
• USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity - Nature
• An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses - Nature
• Role of CD47 in tumor immunity: a potential target for combination therapy - Nature
• Advanced HER2-negative GC/GEJC: PD-1/CTLA-4 plus CD47 blockade shows high response in first line - Vera Health
• ALX Oncology (ALXO) Jefferies London Healthcare Conference 2025 Summary - Quartr
• Engineered CD47 protects T cells for enhanced antitumour immunity - Nature
• Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition - Nature
• Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect - Nature
• CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation - Nature
• An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy - Nature
• Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response - PNAS
• Nanoscale imaging of CD47 informs how plasma membrane modifications shape apoptotic cell recognition - Nature
• Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells - Nature
• Reviving exhausted immune cells boosts tumor elimination - Medical Xpress
• CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth - Nature
• Airway epithelial CD47 plays a critical role in inducing influenza virus-mediated bacterial super-infection - Nature
• RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation - Nature
• Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker - Nature
• STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma - Nature
• HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models - Nature
• Structure of the human marker of self 5-transmembrane receptor CD47 - Nature
• Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow - PNAS
• Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication - Nature
• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma - The New England Journal of Medicine
• IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding t - Nature
• Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment - Nature
• Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma - Nature
• CD47 Knock-Out Using CRISPR-Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo - Wiley & Sons
• CD47 is required for mesenchymal progenitor proliferation and fracture repair - Nature
• Ubiquitination of CD47 Regulates Innate Anti‐Tumor Immune Response - Wiley & Sons
• Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody - Nature
• Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice - Nature
• A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer - Nature
• Pfizer terminates study of CD47 in blood cancer due to low recruitment - Clinical Trials Arena
• A metabolic role for CD47 in pancreatic β cell insulin secretion and islet transplant outcomes - Science | AAAS
• Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion - Nature
• Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model - Nature
• Peninsula biotech company sets two clinical trials to revive its cancer-fighting fortunes - The Business Journals
• Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells - Nature
• Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity - Wiley & Sons
• ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Clinical Trials Arena
• The magrolimab trial halt highlights the uncertainties in anti-CD47 immunotherapy - Clinical Trials Arena
• Effect of CD47 Blockade on Vascular Inflammation - The New England Journal of Medicine
• Catechin suppresses HNSC via STXBP1 dependent inhibition of macrophage infiltration and CD47 mediated immune evasion - Nature
• CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction - Nature
• m6A-methylated KCTD21-AS1 regulates macrophage phagocytosis through CD47 and cell autophagy through TIPR - Nature
• The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivity - Science | AAAS
• Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo - Nature
• Targeted Delivery of miR-34a via Anti-CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer - Wiley Online Library
• Blocking the CD47-SIRPα interaction reverses the disease phenotype in a polycythemia vera mouse model - Nature
• The DNA damage response pathway regulates the expression of the immune checkpoint CD47 - Nature
• Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis - Nature